Aktienanalyse zu Xilio Therapeutics Inc (XLO)XLOXilio Therapeutics Inc

Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing masked immuno-oncology, or I-O, therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. Its pipeline products include Vilastobart, Efarindodekin alfa, XTX501, and masked T cell engagers. Vilastobart is an investigational masked, Fc-enhanced anti-CTLA-4 designed to block CTLA-4 and deplete regulatory T cells when activated (unmasked) in the tumor microenvironment (TME). XTX501 is a novel bispecific PD-1 / masked IL-2 designed to selectively stimulate PD-1 positive, antigen-experienced T cells and enhance their function. Its masked T cell engager programs consist of PSMA and STEAP1 with co-stimulation and CLDN18.2. The masked T cell engagers include molecules with one or more tumor-associated antigen (TAA) binding domains and a CD3 targeting domain. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Xilio Therapeutics Inc is a good buy right now due to its recent financial turnaround, evidenced by a Q2 2026 revenue of $18.7 million, a 131% increase from the previous year, and a current price of $7.99, which is well below its 52-week high of $12.02. The company's gross margin remains strong at 100%, indicating efficient operations. However, the main risk is its net income loss of $6.37 million in Q2 2026, which highlights ongoing financial challenges.